Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine groups A B C Y W-135 conjugate - GSK

Next Previous
Search
Drug Profile

Meningococcal vaccine groups A B C Y W-135 conjugate - GSK

Alternative Names: GSK-3536819A; GSK3536819; MenABCWY (1st Gen); Meningococcal ABCWY Vaccine; Penmenvy; rMenB + MenACWY

Latest Information Update: 23 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer GSK
  • Class Conjugate vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections

Most Recent Events

  • 16 Apr 2025 US Centers for Disease Control and Prevention’s (CDC) Advisory Committee gives positive recommendation for Meningococcal vaccine groups A B C Y W-135 conjugate
  • 15 Feb 2025 Registered for Meningococcal group A infections (In adolescents, In children, Prevention, In adults) in USA (IM)
  • 15 Feb 2025 Registered for Meningococcal group B infections (In adolescents, In children, Prevention, In adults) in USA (IM)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top